Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study

CYP2C9, CYP2D6, SLCO1B1 (drug-gene interactions in diabetology)

Population-based cohort (n>10,000 diabetics): assessment of drug-gene interaction impact (statins/SLCO1B1, sulfonylureas/CYP2C9, antidepressants/CYP2D6) on microvascular complication risk (retinopathy, nephropathy, neuropathy)

Population-based cohort study evaluating the association between drug-gene interactions (SLCO1B1/statins, CYP2C9/sulfonylureas, CYP2D6/antidepressants) and diabetic microvascular complication risk in a large diabetic cohort. The study identifies associations between certain drug-gene interactions and modified risk of diabetic retinopathy, nephropathy and neuropathy, opening the way for PGx genotyping use not only to avoid acute toxicities but also to model chronic complication risk.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Innovative approach extending PGx beyond acute drug toxicities to chronic disease complications. If confirmed in independent studies, these associations could modify prescribing strategies in diabetics with certain genotypes. To be followed with interest.

large-scale population cohort +2; impact on microvascular complications (relevant in diabetology) +2; innovative approach (PGx + diabetes) +2; Diabetes Obes Metab +1